Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Inetetamab|DRUG: Rapamycin|DRUG: Pyrotinib|DRUG: Chemotherapy
Sponsor: Peking Union Medical College